Brouwer, Emily S.
Bratton, Emily W.
Near, Aimee M.
Sanders, Lynn
Mack, Christina D.
Funding for this research was provided by:
Shire Human Genetic Therapies, Inc., a Takeda company
Article History
Received: 30 April 2020
Accepted: 29 March 2021
First Online: 20 April 2021
Declarations
:
: Because the study utilized existing de-identified patient data, approval from an institutional review board and consent to participate were not required.
: Not applicable.
: This research was funded by Shire Human Genetic Therapies, Inc., a Takeda company. ESB is a full-time employee of Takeda Pharmaceutical Company Limited and holds stock/stock options in the company; EB, AN, and CDM are employees of IQVIA, which received funding from Shire Human Genetic Therapies, Inc., a Takeda company, to conduct this analysis. LS is a full-time employee of and holds stock/stock options in Takeda Pharmaceutical Company Limited.